How GLP-1 medications affect food cravings
Part of Hormones & metabolism clinical trials.
This study looks at how GLP-1 medications (like Mounjaro) affect your food cravings and eating when you see food ads. If you join, you'll help researchers understand how these medicines work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a BMI over 25 (overweight or obesity).
- You are taking an injectable tirzepatide (like Mounjaro) at a dose of at least 7.5 mg, as prescribed.
- You are not taking any other incretin-based diabetes or weight-loss medications except your GLP-1.
- You speak English fluently.
- You have a smartphone that can access the study app.
- You have not been diagnosed with a cognitive or physical disability, or epilepsy, and you're not taking a compounded (custom-mixed) GLP-1.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares how a GLP-1 medication (a drug that helps control blood sugar and weight) changes the way your body stores and uses fat. Researchers will use imaging scans to see these changes over time in people with metabolic syndrome—a cluster of health conditions including high blood pressure, high cholesterol, and excess weight.
This study looks at how starting a GLP-1 medication (like Wegovy or Ozempic) changes your food choices and eating habits. It may help you understand if these medicines work for weight loss.
This study looks at how GLP-1 medications (like semaglutide/Wegovy or tirzepatide/Mounjaro) change your sense of taste and eating habits while losing weight. If you are 18–60, have obesity, and have been taking one of these drugs for at least 12 weeks, you may qualify.
This study looks at how a medication that mimics a natural gut hormone affects brain activity related to appetite in people with healthy weight or obesity. It may help researchers find new ways to treat obesity.
This study tests the diabetes/weight-loss drug tirzepatide (Mounjaro) in young adults aged 18–26 who have obesity and either Prader-Willi syndrome, hypothalamic obesity, or general obesity. It looks at whether a weekly injection can help with weight management.
This study looks at how weight-loss medications affect appetite and the hormones that control hunger. It may help people who are starting or already taking these medications understand how they work and manage their weight better.
Hear when a new GLP-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.